balovaptan + itraconazole

**balovaptan + itraconazole** is a combination of balovaptan, a selective small molecule antagonist of the vasopressin 1a receptor (V1aR), and itraconazole, a triazole antifungal agent and potent CYP3A4 inhibitor. Balovaptan is an investigational drug developed primarily for the treatment of autism spectrum disorder (ASD) due to its ability to modulate social behavior by reducing vasopressin signaling in the brain. Itraconazole, normally used for fungal infections, is employed in this context to inhibit CYP3A4, a major enzyme responsible for the metabolism of balovaptan, thereby increasing its systemic exposure. The combination has been studied in healthy volunteers to assess the pharmacokinetic interactions, showing that itraconazole increases balovaptan blood levels by at least 3.1-fold. Balovaptan is under development and has not yet been approved for clinical use, while itraconazole is an approved antifungal agent[1][2][4].

Other names

balovaptan + itraconazoleRO5285119 + itraconazole